Antibiotics Crisis Needs Focused Global Approach “Similar To AIDS” – Conference Told
This article was originally published in The Pink Sheet Daily
A solution to global antibiotics resistance will need co-ordination, focused drug innovation and the selective use of new medicines, in a manner not unlike that which turned HIV from a terminal illness into a chronic condition, participants at the Pharma Summit 2015 are told.
You may also be interested in...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.